Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 23
Treatment-assignment count: 0
Stratification count: 1
NSCLC · Therapy Not Normalized
KRAS G12D is flagged as manual review required because public trials show inclusion required evidence in 28 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 23
Treatment-assignment count: 0
Stratification count: 1
Threshold count: 25
Common snippets: BRAF V600E | EGFR exon 19 deletion | KRAS G12C
Threshold label: Moderate
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Low
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT02642042 | https://clinicaltrials.gov/study/NCT07291037 | https://clinicaltrials.gov/study/NCT02417701 | https://clinicaltrials.gov/study/NCT04250545 | https://clinicaltrials.gov/study/NCT02607813 | https://clinicaltrials.gov/study/NCT01829217 | https://clinicaltrials.gov/study/NCT00858403 | https://clinicaltrials.gov/study/NCT01124864 | https://clinicaltrials.gov/study/NCT06563999 | https://clinicaltrials.gov/study/NCT00548093 | https://clinicaltrials.gov/study/NCT07542704 | https://clinicaltrials.gov/study/NCT06416410 | https://clinicaltrials.gov/study/NCT05383898 | https://clinicaltrials.gov/study/NCT06403436 | https://clinicaltrials.gov/study/NCT04302025 | https://clinicaltrials.gov/study/NCT05119933 | https://clinicaltrials.gov/study/NCT06300177 | https://clinicaltrials.gov/study/NCT05009329 | https://clinicaltrials.gov/study/NCT05005234 | https://clinicaltrials.gov/study/NCT04165031 | https://clinicaltrials.gov/study/NCT06008288 | https://clinicaltrials.gov/study/NCT06208124 | https://clinicaltrials.gov/study/NCT07286149 | https://clinicaltrials.gov/study/NCT04006301 | https://clinicaltrials.gov/study/NCT05445843 | https://clinicaltrials.gov/study/NCT05397093 | https://clinicaltrials.gov/study/NCT05989542 | https://clinicaltrials.gov/study/NCT04427072